{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T10:43:06Z","timestamp":1771756986686,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10067-025-07644-0","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T22:28:19Z","timestamp":1755728899000},"page":"3857-3868","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transforming rheumatoid arthritis care: dynamic budget impact models with ACR to DAS28 mapping for anti-TNFs, JAK inhibitors, and interleukins"],"prefix":"10.1007","volume":"44","author":[{"given":"Ahmed","family":"Al-Jedai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajer","family":"Al-Mudaiheem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayef","family":"Alghanim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibraheem","family":"Alhomood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bedor","family":"Alomari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad","family":"Alzuriqan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalidah","family":"Alonazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratik","family":"Dhopte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8078-5597","authenticated-orcid":false,"given":"Rita El","family":"Ojeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"7644_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9062008","volume":"9","author":"J-W Kim","year":"2020","unstructured":"Kim J-W, Suh C-H (2020) Systemic manifestations and complications in patients with rheumatoid arthritis. J Clin Med 9:2008. https:\/\/doi.org\/10.3390\/jcm9062008","journal-title":"J Clin Med"},{"key":"7644_CR2","first-page":"58","volume":"31","author":"I Rupp","year":"2004","unstructured":"Rupp I, Boshuizen HC, Jacobi CE et al (2004) Comorbidity in patients with rheumatoid arthritis: effect on health-related quality of life. J Rheumatol 31:58\u201365","journal-title":"J Rheumatol"},{"key":"7644_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","volume":"41","author":"K Almutairi","year":"2021","unstructured":"Almutairi K, Nossent J, Preen D et al (2021) The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int 41:863\u2013877. https:\/\/doi.org\/10.1007\/s00296-020-04731-0","journal-title":"Rheumatol Int"},{"key":"7644_CR4","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.14362","volume":"10","author":"SA Mir","year":"2022","unstructured":"Mir SA, Noor M, Manzar MD et al (2022) Prevalence of rheumatoid arthritis and diagnostic validity of a prediction score, in patients visiting orthropedic clinics in the Madinah region of Saudi Arabia: a retrospective cross-sectional study. PeerJ 10:e14362. https:\/\/doi.org\/10.7717\/peerj.14362","journal-title":"PeerJ"},{"key":"7644_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11010-022-04492-3","volume":"478","author":"P Prasad","year":"2023","unstructured":"Prasad P, Verma S, Surbhi et al (2023) Rheumatoid arthritis: advances in treatment strategies. Mol Cell Biochem 478:69\u201388. https:\/\/doi.org\/10.1007\/s11010-022-04492-3","journal-title":"Mol Cell Biochem"},{"key":"7644_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82:3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"key":"7644_CR7","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","volume":"78","author":"S Safiri","year":"2019","unstructured":"Safiri S, Kolahi AA, Hoy D et al (2019) Global, regional and national burden of rheumatoid arthritis 1990\u20132017: a systematic analysis of the global burden of disease study 2017. Ann Rheum Dis 78:1463\u20131471. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215920","journal-title":"Ann Rheum Dis"},{"key":"7644_CR8","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1136\/annrheumdis-2019-eular.4642","volume":"78","author":"NN Coy","year":"2019","unstructured":"Coy NN, Hyrich K, Pavitt S et al (2019) FRI0684 novel mapping function illustrates nonlinearity between trial ACR response, DAS28 change and EULAR response criteria. Ann Rheum Dis 78:1040\u20131041. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.4642","journal-title":"Ann Rheum Dis"},{"key":"7644_CR9","unstructured":"Tice J, Kumar V, Chapman R, Walsh J et al (2019) Janus kinase inhibitors for rheumatoid arthritis: effectiveness and value. Institute for clinical and economic review. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_RA_Evidence_Report_112619-2.pdf"},{"key":"7644_CR10","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song I et al (2019) Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 71:1788\u20131800. https:\/\/doi.org\/10.1002\/art.41032","journal-title":"Arthritis Rheumatol"},{"key":"7644_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03358-x","volume":"26","author":"R Van Vollenhoven","year":"2024","unstructured":"Van Vollenhoven R, Strand V, Takeuchi T et al (2024) Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial. Arthritis Res Ther 26:143. https:\/\/doi.org\/10.1186\/s13075-024-03358-x","journal-title":"Arthritis Res Ther"},{"key":"7644_CR12","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/art.40803","volume":"71","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Strand V, Tanaka Y et al (2019) Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study. Arthritis Rheumatol 71:878\u2013891. https:\/\/doi.org\/10.1002\/art.40803","journal-title":"Arthritis Rheumatol"},{"key":"7644_CR13","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, Van Der Heijde D et al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376:652\u2013662. https:\/\/doi.org\/10.1056\/NEJMoa1608345","journal-title":"N Engl J Med"},{"key":"7644_CR14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","volume":"130","author":"LW Moreland","year":"1999","unstructured":"Moreland LW, Schiff MH, Baumgartner SW et al (1999) Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 130:478\u2013486. https:\/\/doi.org\/10.7326\/0003-4819-130-6-199903160-00004","journal-title":"Ann Intern Med"},{"key":"7644_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/art.30158","volume":"63","author":"JM Kremer","year":"2011","unstructured":"Kremer JM, Blanco R, Brzosko M et al (2011) Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu. Arthritis Rheum 63:609\u2013621. https:\/\/doi.org\/10.1002\/art.30158","journal-title":"Arthritis Rheum"},{"key":"7644_CR16","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F et al (1999) Infliximab (chimeric anti-tumour necrosis factor \u03b1 monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932\u20131939. https:\/\/doi.org\/10.1016\/S0140-6736(99)05246-0","journal-title":"Lancet"},{"key":"7644_CR17","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1002\/art.20568","volume":"50","author":"EW St. Clair","year":"2004","unstructured":"St. Clair EW, Van Der Heijde DMFM, Smolen JS et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432\u20133443. https:\/\/doi.org\/10.1002\/art.20568","journal-title":"Arthritis Rheum"},{"key":"7644_CR18","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1136\/annrheumdis-2013-203695","volume":"73","author":"E Keystone","year":"2014","unstructured":"Keystone E, Landew\u00e9 R, Van Vollenhoven R et al (2014) Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Ann Rheum Dis 73:2094\u20132100. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203695","journal-title":"Ann Rheum Dis"},{"key":"7644_CR19","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker J-C, Schiff M et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor \u03b1 inhibition. N Engl J Med 353:1114\u20131123. https:\/\/doi.org\/10.1056\/NEJMoa050524","journal-title":"N Engl J Med"},{"key":"7644_CR20","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti\u2013tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793\u20132806. https:\/\/doi.org\/10.1002\/art.22025","journal-title":"Arthritis Rheum"},{"key":"7644_CR21","doi-asserted-by":"publisher","first-page":"S412","DOI":"10.1016\/j.jval.2020.08.090","volume":"23","author":"H Almodaimegh","year":"2020","unstructured":"Almodaimegh H, Alrumaih A, Alabdulkarim HAA et al (2020) PBI12 budget impact analysis of baricitinib for the management of moderate-to-severe rheumatoid arthritis in the Kingdom of Saudi Arabia. Value Health 23:S412. https:\/\/doi.org\/10.1016\/j.jval.2020.08.090","journal-title":"Value Health"},{"key":"7644_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40273-019-00829-x","volume":"38","author":"E Wehler","year":"2020","unstructured":"Wehler E, Boytsov N, Nicolay C et al (2020) A budget impact and cost per additional responder analysis for baricitinib for the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to tumor necrosis factor inhibitors in the USA. Pharmacoeconomics 38:39\u201356. https:\/\/doi.org\/10.1007\/s40273-019-00829-x","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 2","key":"7644_CR23","doi-asserted-by":"publisher","first-page":"S412","DOI":"10.1016\/j.jval.2020.08.091","volume":"23","author":"M Farghally","year":"2020","unstructured":"Farghally M, Sara Ahmad MA, Sharma Y et al (2020) PBI13 budget impact analysis to assess the impact of adalimumab-atto (biosimilar) compared to adalimumab in autoimmune diseases in United Arab Emirates. Value in Health 23(Suppl 2):S412. https:\/\/doi.org\/10.1016\/j.jval.2020.08.091","journal-title":"Value in Health"},{"key":"7644_CR24","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.18553\/jmcp.2018.17220","volume":"24","author":"L Claxton","year":"2018","unstructured":"Claxton L, Taylor M, Soonasra A et al (2018) An economic evaluation of tofacitinib treatment in rheumatoid arthritis after methotrexate or after 1 or 2 TNF inhibitors from a U.S. payer perspective. J Manag Care Spec Pharm 24:1010\u20131017. https:\/\/doi.org\/10.18553\/jmcp.2018.17220","journal-title":"J Manag Care Spec Pharm"},{"key":"7644_CR25","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1007\/s12325-021-01867-8","volume":"38","author":"M Osiri","year":"2021","unstructured":"Osiri M, Dilokthornsakul P, Chokboonpium S et al (2021) Budget impact of sequential treatment with biologics, biosimilars, and targeted synthetic disease-modifying antirheumatic drugs in Thai patients with rheumatoid arthritis. Adv Ther 38:4885\u20134899. https:\/\/doi.org\/10.1007\/s12325-021-01867-8","journal-title":"Adv Ther"},{"key":"7644_CR26","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1007\/s10067-020-05087-3","volume":"39","author":"F Navarro","year":"2020","unstructured":"Navarro F, Martinez-Sesmero JM, Balsa A et al (2020) Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain. Clin Rheumatol 39:2919\u20132930. https:\/\/doi.org\/10.1007\/s10067-020-05087-3","journal-title":"Clin Rheumatol"},{"key":"7644_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.55563\/clinexprheumatol\/3f60yv","volume":"43","author":"J Fournier","year":"2025","unstructured":"Fournier J, Boussat B, Dervaux B, Gaudin P, Romand X (2025) Cost-utility of tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in France: a multi-state Markov model analysis. Clin Exp Rheumatol 43:62\u201369. https:\/\/doi.org\/10.55563\/clinexprheumatol\/3f60yv","journal-title":"Clin Exp Rheumatol"},{"key":"7644_CR28","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1080\/13696998.2024.2379212","volume":"27","author":"K Clarke","year":"2024","unstructured":"Clarke K, Ainslie-Garcia M, Ferko N, Shastri K (2024) Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective. J Med Econ 27:952\u2013962. https:\/\/doi.org\/10.1080\/13696998.2024.2379212","journal-title":"J Med Econ"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07644-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07644-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07644-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:25:51Z","timestamp":1760365551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07644-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7644"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07644-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}